2024
Onco-Nephrology Symposium
SEPTEMBER 13—14, 2024
IN-PERSON / VIRTUAL
ZUCKERMAN RESEARCH CENTER
NEW YORK CITY
Memorial Sloan Kettering Cancer Center
Overview

The 2024 Onco-Nephrology Symposium welcomes all members of the healthcare team who manage patients with both cancer and kidney disease.

This year’s program embraces the multidisciplinary nature of onco-nephrology and features experts in plasma cell disorders such as multiple myeloma, amyloidosis, monoclonal gammopathies as well as renowned speakers on CAR T cell, other biologic therapies, thrombotic microangiopathy, and cardio-renal syndromes.

The goal of this forum is to allow academicians, clinicians, and clinical experts to have personal exchanges and robust discussions in order to enhance the clinical experiences and outcomes of patients.

CALL FOR ABSTRACTS

We invite the submission of abstracts relating to clinical care of patients with cancer and kidney disease. The objective is to stimulate discussion on the evaluation and management of kidney injury in patients with cancer. The type of research can be qualitative and/or quantitative and have a focus in basic science, clinical research, public health, or epidemiology. Authors may submit abstracts of completed work or work in progress within the past 12 months.

Abstracts must be submitted by Friday, August 9, 2024.
Educational Objectives

At the conclusion of this program, attendees will be able to:

- Strategize a treatment plan for the patient with MGRS as part of a multidisciplinary team
- Effectively utilize novel diagnostic techniques to diagnose monoclonal disorders
- Formulate a treatment plan for kidney transplant patients who receive CAR T cell therapy
- Outline a comprehensive assessment and treatment of thrombotic microangiopathy
- Assimilate genetic testing data in the evaluation of thrombotic microangiopathy
- Review assessment and management of glomerular disorders in cancer patients
- Apprehend modern therapeutic approaches to small renal masses and cancers of the kidney
- Recognize renal and non renal toxicities of modern cancer therapy

Who Should Attend

The target audience includes physicians, advanced practice providers, nurses, medical students, and other healthcare professionals interested in the care of cancer patients with kidney disease.

Early rates available through July 12, 2024:

msk.org/onco-nephrology
MSK Symposium Directors

**Sheron Latcha, MD**  
Program Director, Nephrology Fellowship;  
Attending, Renal Service  
Department of Medicine

**Aisha Shaikh, MBBS**  
Associate Attending, Renal Service  
Department of Medicine

Invited Faculty

**Ala Abudayyeh, MD**  
Director, of Clinical Research,  
Division Section of Nephrology  
MD Anderson Cancer Center  
Houston, TX, USA

**Chris Blosser, MD**  
Director, Fred Hutch Cancer and organ Transplant Clinic;  
Director, UW Transplant Fellowship  
Fred Hutchinson Cancer Center  
Seattle, Washington, USA

**Sandra Herrmann, MD**  
Professor of Medicine  
Mayo Clinic  
Rochester, MN, USA

**Kenar Jhaveri, MD**  
Professor of Medicine;  
Co-Director,  
Onco-Nephrology Services  
Donald and Barbara Zucker School of Medicine at Hofstra / Northwell  
New York, NY, USA

**Sabine Karam, MD**  
Assistant Professor of Medicine  
University of Minnesota  
Minneapolis, MN, USA

**David Kavanagh, PhD**  
Professor of Complement Therapeutic at National Renal Complement Therapeutics Centre  
Freeman Hospital Renal Center  
Newcastle Upon Tyne, England, UK

**Abhijat Kitchlu MD, MSc**  
Staff Nephrologist;  
Clinician Investigator  
University Health Network  
Associate Professor of Medicine  
University of Toronto  
Toronto, ON, Canada

**Nelson Leung, MD**  
Professor of Medicine;  
Program Director,  
Onco-Nephrology Fellowship  
Mayo Clinic  
Rochester, MN, USA
Syed Saad Mahmood, MD, MPH  
System Director, Cardio-Oncology  
St. Francis Hospital & Heart Center  
Roslyn, NY, USA

Glen Markowitz, MD  
Professor of Pathology and Cell Biology;  
Executive Vice Chair for Anatomic Pathology  
Columbia University Irving Medical Center  
New York, NY, USA

Samih Nasr, MD  
Professor of Laboratory Medicine and Pathology  
Mayo Clinic  
Rochester, MN, USA

Carla Nester, MD, MSA, FASN  
Associate Director, Molecular Otolaryngology and Renal Research Laboratories;  
Director, Pediatric Glomerular Disease Clinic;  
Director, Rare Disease Clinic  
University of Iowa Hospitals and Clinics  
Iowa City, IA, USA

Arash Rashidi, MD  
Director, Onco-Nephrology Program  
University Hospitals of Cleveland Westlake, OH, USA

Steven Salvatore, MD  
Associate Professor of Clinical Pathology and Laboratory Medicine  
Weill Cornell Medicine  
New York, NY, USA

Biruh Workaneh, MD  
Professor of Medicine  
MD Anderson Cancer Center  
Houston, TX, USA

MSK Faculty

Lisa Bodei, MD, PhD  
Director, Radiopharmaceutical Therapy Section;  
Attending, Molecular Imaging and Therapy Service  
Department of Radiology

Jessica Chapman, PhD  
Director, Clinical Proteomics Assistant Attending, Hematopathology Service  
Department of Pathology and Laboratory Medicine

Sherrilyn Eudoxie, RN  
Clinical Nurse

James Flory, MD  
Associate Attending, Endocrinology Service  
Department of Medicine;  
Associate Professor of Medicine

Samuel Funt, MD  
Assistant Attending, Genitoruinary Oncology Service  
Department of Medicine;  
Assistant Professor of Medicine
Ilya Glezerman, MD
Attending; Clinical Director, Renal Service
Department of Medicine

Victoria Gutgarts, MD
Assistant Attending, Renal Service
Department of Medicine; Assistant Professor of Medicine

Ari Hakimi, MD
Associate Attending, Urology Service
Department of Surgery; Associate Professor of Surgery

Hazma Hashimi, MD
Assistant Attending, Myeloma Service
Department of Medicine

Hani Hassoun, MD
Attending, Myeloma Service
Department of Medicine; Professor of Medicine

Malin Hulcrantz, MD
Associate Attending, Myeloma Service
Department of Medicine; Associate Professor of Medicine

Insara Jaffar, MBBS
Assistant Attending, Renal Service
Department of Medicine; Assistant Professor of Medicine

Edgar Jaimes, MD
Chief, Renal Service
Department of Medicine; Professor of Medicine

Heather Landau, MD
Director, Amyloidosis Program; Associate Attending, Bone Marrow Transplant and Cellular Therapy Services
Department of Medicine

Jennifer Liu, MD, FACC
Chief, Cardiology Service; Director Cardiovascular Laboratories
Department of Medicine

Monica Maguire, RN
Clinical Nurs

Sham Mailankody, MBBS
Associate Attending; Clinical Director, Cellular Therapy Service; Research Director, Myeloma Service
Department of Medicine; Associate Professor of Medicine

Kazunori Murata, PhD
Director, Ralph Lauren Center Laboratory

Karlo Perica, MD
Assistant Attending, Immunology Program Sloan Kettering Institute; Assistant Professor of Medicine

Michael Scordo, MD
Assistant Attending, Bone Marrow Transplant and Cellular Therapy Services
Department of Medicine

Saad Usmani, MD
Chief, Myeloma Service
Department of Medicine

Martin Voss, MD
Associate Attending; Clinical Director, Genitourinary Medical Oncology Service
Department of Medicine; Associate Professor of Medicine
Day 1 Schedule

Friday, September 13

7:00 AM  In-Person Registration and Breakfast
7:55 AM  Virtual Zoom Sign-on
8:00 AM  Introductory Remarks
        Sheron Latcha, MD
        Aisha Shaikh, MBBS

This is How We Do It
MODERATOR: Sandra Herrmann, MD

8:05 AM  Department of Medicine Grand Rounds
How I Treat Monoclonal Gammopathy of Renal Significance (MGRS)
        Nelson Leung, MD

9:00 AM  Break
9:15 AM  How I Treat Multiple Myeloma
        Saad Usmani, MD
9:40 AM  How I Treat AL Amyloidosis with Kidney Involvement
        Heather Landau, MD
10:05 AM  How I Use Serum Free Light Chains in Clinical Practice
        Malin Hulcrantz, MD
10:20 AM  Q&A and Panel Discussion
10:30 AM  Break

Monoclonal Proteins: Getting to the Heart of the Matter
MODERATOR: Sabine Karam, MD

10:45 AM  How I Assess Treatment Response in Plasma Cell Disorders
        Hani Hassoun, MD
11:05 AM  Mass Spectrometry Made Simple
        Jessica Chapman, PhD
11:20 AM  Newer Methodologies to Detect Monoclonal Proteins in the Blood and Urine in Monoclonal Gammopathy of Renal Significance (MGRS)
        Kazunori Murata, PhD
11:35 AM  Newer Methodologies to Detect Monoclonal Proteins on the Kidney Biopsy
        Samih Nasr, MD
11:55 AM  Q&A and Panel Discussion
12:05 PM  Lunch Break
**CAR T Cell Therapy**

**MODERATOR:** Biruh Workaneh, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:05 PM</td>
<td><strong>Next Generation Therapy: CARTs and Beyond</strong></td>
<td>Sham Mailankody, MBBS</td>
</tr>
<tr>
<td>1:25 PM</td>
<td><strong>CAR T Therapy in Patients with MM and ESRD</strong></td>
<td>Hazma Hashimi, MD</td>
</tr>
<tr>
<td>1:45 PM</td>
<td><strong>CAR T Alphabet Soup</strong></td>
<td>Karlo Perica, MD</td>
</tr>
<tr>
<td>2:05 PM</td>
<td><strong>Q&amp;A and Panel Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>2:15 PM</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
<tr>
<td>2:30 PM</td>
<td><strong>CARs and Solid Organ Transplant</strong></td>
<td>Chris Blosser, MD</td>
</tr>
<tr>
<td>2:50 PM</td>
<td><strong>Q&amp;A and Panel Discussion</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Renal and Testicular Cancer**

**MODERATOR:** Kenar Jhaveri, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>2:55 PM</td>
<td><strong>Modern Approach to the Diagnosis and Treatment of Renal Cancer</strong></td>
<td>Martin Voss, MD</td>
</tr>
<tr>
<td>3:10 PM</td>
<td><strong>Modern Approach to the Diagnosis and Treatment of Small Renal Masses</strong></td>
<td>Ari Hakimi, MD</td>
</tr>
<tr>
<td>3:25 PM</td>
<td><strong>Modern Approach to the Diagnosis and Treatment of Testicular Cancer</strong></td>
<td>Samuel Funt, MD</td>
</tr>
<tr>
<td>3:40 PM</td>
<td><strong>Q&amp;A and Panel Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>3:50 PM</td>
<td><strong>Break</strong></td>
<td></td>
</tr>
</tbody>
</table>

**Glomerular and Tubular Matters**

**MODERATOR:** Abhijat Kitchlu MD, MSc

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:05 PM</td>
<td><strong>VEGF Inhibitors and TKIs: Stopping and Restarting After Kidney Injury</strong></td>
<td>Sandra Herrmann, MD</td>
</tr>
<tr>
<td>4:20 PM</td>
<td><strong>Glomerular Diseases in Chronic GVHD</strong></td>
<td>Ilya Glezerman, MD</td>
</tr>
<tr>
<td>4:35 PM</td>
<td><strong>Management of BK Nephropathy Post-SCT</strong></td>
<td>Ala Abudayyeh, MD</td>
</tr>
<tr>
<td>4:50 PM</td>
<td><strong>Q&amp;A and Panel Discussion</strong></td>
<td></td>
</tr>
</tbody>
</table>

**5:00 PM** **Networking and Poster Reception (LOBBY)**

We invite attendees to a networking reception from 5:00—6:00 PM with hors d’oeuvres and refreshments.
# Day 2 Schedule

## Saturday, September 14

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>In-Person Registration and Breakfast</td>
</tr>
<tr>
<td>8:50 AM</td>
<td>Virtual Zoom Sign-on</td>
</tr>
<tr>
<td>8:55 AM</td>
<td><strong>Day 2 Introduction</strong></td>
</tr>
<tr>
<td></td>
<td>Sheron Latcha, MD</td>
</tr>
<tr>
<td></td>
<td>Aisha Shaikh, MBBS</td>
</tr>
</tbody>
</table>

### Thrombotic Microangiopathy
**Moderator:** Nelson Leung, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 AM</td>
<td><strong>TMA: Demystifying the Complement Pathway</strong></td>
</tr>
<tr>
<td></td>
<td>Carla Nester, MD, MSA, FASN</td>
</tr>
<tr>
<td>9:20 AM</td>
<td>Complement Studies and Interpreting Genetic Testing</td>
</tr>
<tr>
<td></td>
<td>David Kavanagh, PhD</td>
</tr>
<tr>
<td>9:40 AM</td>
<td><strong>Role of Eculizumab and Other Therapies in Non-TA-TMA</strong></td>
</tr>
<tr>
<td></td>
<td>David Kavanagh, PhD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td><strong>Let’s Go to the Data: Eculizumab, Narsoplimab in TA-TMA</strong></td>
</tr>
<tr>
<td></td>
<td>Michael Scordo, MD</td>
</tr>
<tr>
<td>10:20 AM</td>
<td>Q&amp;A and Panel Discussion</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Break</td>
</tr>
</tbody>
</table>

### Beyond the Kidneys
**Moderator:** Edgar Jaimes, MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45 AM</td>
<td><strong>Diagnosis, Management, and Prognosis of Cardiac Amyloidosis</strong></td>
</tr>
<tr>
<td></td>
<td>Jennifer Liu, MD, FACC</td>
</tr>
<tr>
<td>11:00 AM</td>
<td><strong>An Update on Radiation Nephropathy — From EBRT to Therapeutic Isotopes</strong></td>
</tr>
<tr>
<td></td>
<td>Lisa Bodei, MD, PhD</td>
</tr>
<tr>
<td>11:15 AM</td>
<td><strong>Endocrine Toxicities From ICPI</strong></td>
</tr>
<tr>
<td></td>
<td>James Flory, MD</td>
</tr>
<tr>
<td>11:30 AM</td>
<td><strong>Updates in the Management of Cancer Treatment-Related Cardiac Toxicities</strong></td>
</tr>
<tr>
<td></td>
<td>Syed Saad Mahmood, MD, MPH</td>
</tr>
<tr>
<td>11:45 AM</td>
<td>Q&amp;A and Panel Discussion</td>
</tr>
<tr>
<td>11:55 AM</td>
<td>Lunch Break</td>
</tr>
</tbody>
</table>
## Case Discussions

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Moderator</th>
<th>Pathologists</th>
<th>Panelists</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 PM</td>
<td><strong>Moderator</strong></td>
<td>Arash Rashidi, MD</td>
<td>Steven Salvatore, MD</td>
<td>Glen Markowitz, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Pathologists</strong></td>
<td></td>
<td>Steven Salvatore, MD</td>
<td>Glen Markowitz, MD</td>
</tr>
<tr>
<td></td>
<td><strong>Panelists</strong></td>
<td></td>
<td>Nelson Leung, MD</td>
<td>Abhijat Kitchlu, MD, MS</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Insara Jaffar, MBBS</td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td><strong>Announcement of Poster Winners</strong></td>
<td>Victoria Gutgarts, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:10 PM</td>
<td><strong>Closing Remarks</strong></td>
<td>Sheron Latcha, MD</td>
<td>Aisha Shaikh, MBBS</td>
<td></td>
</tr>
<tr>
<td>2:20 PM</td>
<td><strong>Adjournment</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Exclusive Discount Offer

Attendees of the Onco-Nephrology Symposium are eligible for a special **$75 discount** for the *Inaugural Symposium on Kidney Transplantation in Plasma Cell Disorders*, scheduled for the preceding day, Thursday, September 12.
Accreditation

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC/CC Recognition Statements

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

- 11.00 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program; and

- 11.00 Lifelong Learning (CME) credits in the American Board of Pathology’s (ABPath) Continuing Certification program.

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABPath MOC/CC credit.

An application for NCPD credits has been submitted.
Registration Details

This symposium offers participants the choice of attending either in person or virtually.

In-person registrants will be provided continental breakfast, lunch, and refreshment breaks. Contact cme@mskcc.org at least one week prior to the course if you have any special dietary requests or require any specific accommodations for joining us onsite.

Discounted registration is available for specific groups. Visit the symposium website for additional details: msk.org/Onco-Nephrology

Symposium Fees

<table>
<thead>
<tr>
<th>Category</th>
<th>Early*</th>
<th>General</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians (MDs, PhDs, and DOs)</td>
<td>$400</td>
<td>$450</td>
</tr>
<tr>
<td>Advanced Practice Providers</td>
<td>$300</td>
<td>$350</td>
</tr>
<tr>
<td>Residents, Fellows, Nurses, and Other Healthcare Providers</td>
<td>$200</td>
<td>$250</td>
</tr>
<tr>
<td>Industry Professionals**</td>
<td>n/a</td>
<td>$750</td>
</tr>
<tr>
<td>MSK Employees</td>
<td>Complimentary</td>
<td></td>
</tr>
</tbody>
</table>

*Apply promotion code ONCNEPH24 during registration to take advantage of early discounted rates. Offer valid through July 12, 2024.

**An “industry professional” is defined as any individual, regardless of their profession type (such as MDs, PhDs, APPs, RNs, etc.) that is employed by an ineligible company.